Endomed Plans To Re-Launch AAA Device In Europe, Following MDA Alert
This article was originally published in The Gray Sheet
Executive Summary
Patient deaths related to Endomed, Inc.'s Endofit endoluminal aortic stent graft resulted from errors made by physicians who did not follow device instructions, the Phoenix-based company maintains
You may also be interested in...
EndoMed Thoracic Stent Graft Requires Separate IDE – FDA Warning Letter
EndoMed envisions a late summer European launch for its pre-loaded aortomonoiliac and thoracic Endofit endoluminal stent grafts
EndoMed Thoracic Stent Graft Requires Separate IDE – FDA Warning Letter
EndoMed envisions a late summer European launch for its pre-loaded aortomonoiliac and thoracic Endofit endoluminal stent grafts
U.S. AAA Stent Graft Market Reaching Capacity As Larger Players Weigh In
Abdominal aortic aneurysm (AAA) stent graft technology ranks high on the research agendas of several manufacturers this year, with a wave of first and next-generation product launches anticipated